Sagient Research Products About Us Contact Us
Search BioMedTracker  
  Drugs Covered: 5,548
  Catalysts Covered: 5,978
  Revenue Models: 446
  Companies Covered: 1,364
  Companies Evaluated:  26
Search
Catalysts Drug Profiles
Impact Events Company Profiles
Target    Indication   
Trials    All   
Thought Leader Opinion   

Sample Reports
01/31/12 Early 2012 BMT Outlook Report
01/13/12 JP Morgan Conference Review
01/09/12 2011 Post-ASH Report
12/08/11 2011 Post-AASLD/HCV Update Report
12/07/11 2011 Post-CTAD Report
12/06/11 2011 Pre-ASH Report
12/02/11 2011 ASH Planner
10/28/11 2011 Pre-AASLD/HCV Update Report
10/25/11 2011 BioMedTracker AASLD Planner
10/20/11 2011 BioMedTracker ACR Planner
10/19/11 BioMedTracker FDA Report Update - 2011
10/04/11 Q4 2011 BMT Outlook Report
09/15/11 PDUFA V Report
09/09/11 Xarelto Advisory Panel   More...
Date Report Title
01/31/12 Early 2012 BMT Outlook Report
01/13/12 JP Morgan Conference Review
01/09/12 2011 Post-ASH Report
12/08/11 2011 Post-AASLD/HCV Update Report
12/07/11 2011 Post-CTAD Report
12/06/11 2011 Pre-ASH Report
12/02/11 2011 ASH Planner
11/08/11 BioMedTracker BIO Study - Strategic Resource Management Conference
10/28/11 2011 Pre-AASLD/HCV Update Report
10/25/11 2011 BioMedTracker AASLD Planner
10/20/11 2011 BioMedTracker ACR Planner
10/19/11 BioMedTracker FDA Report Update - 2011
10/04/11 Q4 2011 BMT Outlook Report
09/15/11 PDUFA V Report
09/09/11 Xarelto Advisory Panel
08/15/11 2011 BioMedTracker Post-ADA Report
07/25/11 Dapagliflozin Advisory Panel
07/11/11 2011 BioMedTracker Post-ASCO Report
07/11/11 Q3 2011 BMT Outlook Report
06/22/11 2011 ADA Planner
06/06/11 2011 ASCO Weekend Update
05/19/11 2011 Pre-ASCO Report
05/04/11 BioMedTracker 2011 ASCO Planner
04/29/11 Hepatitis C Advisory Panel
04/14/11 Q2 2011 BMT Outlook Report
04/05/11 New Evaluated Company - Lexicon Pharmaceuticals (LXRX)
02/15/11 New BioMedTracker Likelihood of Approval Rates
02/03/11 Early 2011 BMT Outlook Report
01/18/11 JP Morgan Conference Review
01/03/11 2010 Post-ASH Report
12/17/10 New Evaluated Company - Gilead Sciences (GILD)
12/07/10 Contrave Advisory Panel
12/01/10 2010 AASLD Report Wrap-Up
11/30/10 2010 Pre-ASH Report
10/25/10 2010 Pre-AASLD/HCV Update Report
10/05/10 Q4 2010 BMT Outlook Report
09/16/10 Lorqess Advisory Panel
09/15/10 Meridia Advisory Panel
08/12/10 2010 Post-ADA Report
08/11/10 2010 BioMedTracker Post-ASCO Report
07/09/10 Q3 2010 BMT Outlook Report
06/21/10 2010 Pre-ADA Report
06/06/10 2010 ASCO Weekend Update
05/20/10 2010 Pre-ASCO Report
04/30/10 2010 BioMedTracker ASCO Planner
04/12/10 2010 Pre-EASL Report
04/08/10 Q2 2010 BMT Outlook Report
04/05/10 BioMedTracker FDA Report Update - 2010
03/17/10 Rheumatoid Arthritis Indication Report
02/04/10 2010 BioMedTracker Outlook Report
01/19/10 JP Morgan Conference Review
12/21/09 2009 Post-ASH Report
11/30/09 2009 Pre-ASH Report
11/19/09 Vivus (VVUS) Coverage Initiation
11/13/09 H1N1 Influenza Pandemic Tracker
11/02/09 2009 Post-ACR Report
10/15/09 ACR Conference Catalysts
09/28/09 Q4 2009 BMT Outlook Report
09/21/09 Hepatitis B Indication Report
07/07/09 2009 Post-ADA Report
06/25/09 2009 Post-ASCO Report
05/31/09 2009 ASCO Weekend Update
05/28/09 2009 Pre-ADA Report
05/14/09 2009 Pre-ASCO Report
04/09/09 Diabetes Regulatory Update
03/24/09 Diabetes Approval Timing Update
02/06/09 2009 BioMedTracker Outlook Report
12/18/08 2008 Post-ASH Report
12/02/08 2008 ASH Preview
09/25/08 Cougar (CGRB) Coverage Initiation
08/14/08 2008 Post-ICAD Report
07/24/08 2008 Pre-ICAD Report
07/10/08 Diabetes Update Following 2008 ADA and FDA Advisory Committee Meetings
06/17/08 2008 Post-ASCO Report
05/30/08 2008 Pre-ADA Report
05/15/08 2008 ASCO Abstract Summary
05/12/08 2008 Pre-ASCO Report
05/05/08 Bipolar Indication Report
02/01/08 2008 BioMedTracker Outlook
01/08/08 FDA Approval Study
12/18/07 2007 Post-ASH Report
12/12/07 Kuvan PDUFA Sensitivity Analysis
12/07/07 Multiple Sclerosis (MS) Indication Report
12/04/07 2007 Pre-ASH Report
11/09/07 BioMarin (BMRN) Valuation Update
10/30/07 2007 AASLD Preview
10/01/07 Salix (SLXP) Coverage Initiation
09/21/07 Catalyst Impact Study
09/21/07 Orexigen (OREX) Coverage Initiation
08/28/07 Schizophrenia Indication Report
07/27/07 HGSI Coverage Initiation
07/09/07 2007 Post-ADA Report
06/21/07 2007 Post-ASCO Report
06/15/07 InterMune Coverage Initiation
05/17/07 2007 Pre-ASCO Report
04/27/07 Spectrum Coverage Initiation
04/13/07 Idiopathic Pulmonary Fibrosis (IPF) Indication Report
03/30/07 2007 Post-ACC Report
03/13/07 HIV Indication Report - Update
03/01/07 CDAD Indication Report
02/23/07 Obesity Indication Report - Update
01/31/07 2007 BioMedTracker Outlook
01/19/07 5 and 10 Year Pipeline Updates
12/20/06 2006 Post-ASH Report
12/08/06 2006 Pre-ASH Report
12/01/06 Glioblastoma Multiforme (GBM) Indication Report
10/30/06 Hereditary Angioedema (HAE) Indication Report
10/20/06 Renovis Coverage Initiation
10/04/06 Coley Coverage Initiation
09/22/06 Hypercholesterolemia/ Dyslipidemia Indication Report
08/31/06 NSCLC Indication Report - Update
07/13/06 Type II Diabetes Indication Report - Update
07/12/06 Renal Cell Cancer Indication Report - Update
06/21/06 2006 Post-ASCO Report
06/20/06 Sepracor Coverage Initiation
06/16/06 2006 Post-ADA Report
05/30/06 2006 ASCO Preview
05/12/06 Insomnia Indication Report - Update
05/08/06 Spreading Agents Indication Report
05/04/06 Panacos Coverage Initiation
05/02/06 HIV Indication Report - Update
04/13/06 Arena Coverage Initiation
04/12/06 Resistant Hypertension Indication Report
03/28/06 Systemic Lupus Erythematosus (SLE) Indication Report
03/17/06 Asthma Indication Report
03/09/06 MannKind Coverage Initiation
03/01/06 Pharmion and GPC Biotech AG Coverage Initiation
02/08/06 HPV Vaccine Report
01/31/06 Cardiome Coverage Initiation
01/24/06 Obesity Indication Report
01/11/06 2006 BioMedTracker Outlook
12/22/05 COPD Indication Report
12/15/05 2005 Post-ASH Report
12/01/05 2005 ASH Catalyst Preview
11/08/05 Hepatitis C Indication Report
10/10/05 HIV/AIDS Indication Report
10/07/05 Alkermes Coverage Initiation
08/29/05 Nabi Coverage Initiation
08/25/05 ACS, CABG, and PCI Indication Report
08/15/05 Renal Cell Cancer Indication Report
07/21/05 Parkinson Disease Indication Report
07/20/05 Ligand Coverage Initiation
07/11/05 Celgene Coverage Initiation
06/29/05 2005 ADA Post-Conference Report
05/25/05 2005 Post ASCO Report
05/10/05 2005 ASCO Preview
05/09/05 Cubist Coverage Initiation
05/02/05 Skin and Skin-Structure Infections Indication Report
04/13/05 NPS Coverage Initiation
03/31/05 Incyte Corporation Coverage Initiation
03/28/05 NSCLC Indication Report
02/25/05 Ischemic Stroke Indication Report
02/11/05 Alzheimer's Disease Indication Report
01/27/05 Hypertension Indication Report
01/14/05 Myelodysplastic Syndrome Indication Report
01/13/05 Type II Diabetes Indication Report
01/06/05 2005 BioMedTracker Outlook
12/14/04 Insomnia Indication Report
12/10/04 Post-ASH Coverage 2004
12/07/04 Wet AMD Indication Report
12/02/04 Pre-ASH Coverage 2004
11/16/04 Multiple Sclerosis Indication Report
11/08/04 Osteoporosis Indication Report
 Questions? Email Customer Support Privacy Policy     Important Legal Disclosure 

Copyright © 2012 Sagient Research Systems, Inc.  All rights reserved. Web2